Back to top
more

Bristol Myers Squibb (BMY)

(Delayed Data from NYSE)

$53.76 USD

53.76
22,196,871

+0.86 (1.63%)

Updated Oct 2, 2024 04:00 PM ET

After-Market: $53.98 +0.22 (0.41%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth C Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 31% (77 out of 252)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Arpita Dutt headshot

Pharma Stock Roundup: Roche Drug Gets Priority Review, EU Nod for Novartis Drug

by Arpita Dutt

It was a pretty slow week with key highlights including regulatory updates from companies like Roche (RHHBY) and Novartis.

    Celldex Ends Phase II Enrollment for Breast Cancer Candidate

    by Zacks Equity Research

    Celldex (CLDX) announces completion of enrollment in METRIC, a phase IIb study, evaluating glembatumumab vedotin for breast cancer treatment.

      Here's Why Clovis Stock Is Up Almost 60% So Far in 2017

      by Zacks Equity Research

      Clovis Oncology (CLVS) stock is on the rise. The company's only approved drug Rubraca is off to an impressive start and is nearing label expansion approval.

        Gilead (GILD) HCV Drug Vosevi Receives Approval in Canada

        by Zacks Equity Research

        Gilead Sciences, Inc.'s (GILD) HCV portfolio receives a boost with the approval of Vosevi in Canada.

          Arpita Dutt headshot

          Pharma Stock Roundup: Multiple Sclerosis Drug Prices in Focus, Mixed Data on BMY's Opdivo

          by Arpita Dutt

          Key highlights this week in the pharmaceutical sector include the launch of a drug pricing probe, a resignation from the President's manufacturing council and data on Bristol-Myers' (BMY) Opdivo.

            Exelixis Submits sNDA for Kidney Cancer Drug Cabometyx

            by Zacks Equity Research

            Exelixis, Inc. (EXEL) submitted its supplemental New Drug Application (sNDA) to the FDA for Cabometyx tablets for patients with previously untreated kidney cancer.

              FDA Accepts Portola's (PTLA) BLA Resubmission for AndexXa

              by Zacks Equity Research

              FDA acknowledges Portola's (PTLA) resubmitted BLA for AndexXa to raise hopes for an urgent need of antidotes for Factor Xa inhibitors in the market.

                Bristol-Myers Opdivo Fails Kidney Cancer Trial CheckMate-214

                by Zacks Equity Research

                Bristol-Myers Squibb Company (BMY) announced disappointing top-line results from the CheckMate-214 trial on Opdivo in renal cell carcinoma.

                  Clovis (CLVS) Focuses on Label Expansion, Rubraca Impresses

                  by Zacks Equity Research

                  Clovis Oncology (CLVS) reported significant increase in Rubraca sales in the second quarter. Moreover, the company is focused on expanding Rubraca's label in second-line ovarian cancer.

                    Gilead (GILD) NDA for HIV Combo Regimen Gets Priority Review

                    by Zacks Equity Research

                    Gilead Sciences, Inc.'s(GILD) NDA for an investigational, fixed-dose combination of bictegravir for the treatment of HIV-1 infection obtained priority review.

                      Nektar's (NKTR) Shares Fall Post Wider Q2 Loss, Revenues Lag

                      by Zacks Equity Research

                      Nektar (NKTR) reports wider-than-expected loss with revenues falling shy of estimates. However, the top line rises year over year, courtesy an increase in product sales and royalty revenues.

                        Arpita Dutt headshot

                        Pharma Stock Roundup: Mylan Misses, Perrigo Tops in Q2, Zynerba Plunges on Study Failure

                        by Arpita Dutt

                        This week, focus was on earnings announcements from companies like Mylan (MYL), Perrigo and Endo.

                          AVEO Pharmaceuticals (AVEO) Q2 Loss Narrower than Expected

                          by Zacks Equity Research

                          AVEO Pharmaceuticals (AVEO) reported narrower-than-expected adjusted loss in the second quarter. Its kidney cancer candidate, tivozanib is nearing approval in EU with positive CHMP recommendation.

                            Celldex (CLDX) Q2 Loss Narrows, Revenues Beat, Shares Up

                            by Zacks Equity Research

                            Celldex Therapeutics, Inc. (CLDX) reported narrower-than-expected loss in Q2 and also beat estimates for sales. Shares rose in after-hours trading on Tuesday.

                              Horizon Pharma (HZNP) Q2 Earnings & Sales Top, Raises View

                              by Zacks Equity Research

                              Horizon Pharma plc (HZNP) topped both earnings and sales estimate in second-quarter 2017 and raised its sales guidance for 2017.

                                Sweta Killa headshot

                                Q2 Earnings Fail to Impress Pharma ETF

                                by Sweta Killa

                                The string of earnings beat failed to boost pharma ETFs.

                                  Infinity (INFI) Q2 Loss Wider than Expected, View Intact

                                  by Zacks Equity Research

                                  Infinity Pharmaceuticals, Inc. (INFI) reported a wider-than-expected loss in second-quarter 2017 due to the termination of an agreement with AbbVie.

                                    Arpita Dutt headshot

                                    Pharma Stock Roundup: Mixed 2Q Results from Pfizer, Bristol-Myers Announces IO Deals

                                    by Arpita Dutt

                                    Pfizer's (PFE) results were mixed while Teva had a dismal quarter with the company missing estimates as well as cutting its outlook and guidance.

                                      Exelixis (EXEL) Q2 Earnings, Sales Beat on Cabometyx Sales

                                      by Zacks Equity Research

                                      Exelixis' (EXEL) second-quarter results were impressive where in both earnings and sales beat estimates driven by strong uptake of Cabometyx.

                                        Aduro (ADRO) Q2 Loss Narrower than Expected, Revenues Top

                                        by Zacks Equity Research

                                        Aduro (ADRO) incurs loss in Q2 but revenues beat estimates. However, the same declines year over year, courtesy a milestone payment from the year-ago quarter.

                                          Clovis (CLVS) Q2 Loss Wider than Expected, Rubraca Impresses

                                          by Zacks Equity Research

                                          Clovis Oncology (CLVS) reported narrower year-over-year loss in the second quarter on the back of impressive Rubraca sales. The company is also actively working on Rubraca's label expansion.

                                            The Zacks Analyst Blog Highlights: Procter & Gamble, Altria, Bristol-Myers, ConocoPhillips and Electronic Arts

                                            by Zacks Equity Research

                                            The Zacks Analyst Blog Highlights: Procter & Gamble, Altria, Bristol-Myers, ConocoPhillips and Electronic Arts

                                              Incyte (INCY) Q2 Loss Wider than Expected, Jakafi Strong

                                              by Zacks Equity Research

                                              Incyte (INCY) reported a wider-than-expected loss in the second quarter but revenues beat expectations.

                                                What's in the Cards for Celldex (CLDX) this Earnings Season?

                                                by Zacks Equity Research

                                                With no approved product in Celldex Therapeutics's (CLDX) portfolio, investor focus will remain on immuno-oncology pipeline, which continues to show impressive results.

                                                  Arpita Dutt headshot

                                                  Key FDA Events to Watch Out for in Aug 2017

                                                  by Arpita Dutt

                                                  Will the FDA follow the recommendation of its advisory panel and give its nod to Dynavax's (DVAX) hepatitis B vaccine?